الصفحة 1
الصفحة 1
Infection control and management of hazardous materials for the dental team
Comprehensive coverage looks at infection control and prevention from the perspective of all dental team members. Easy-to-follow, step-by-step procedures are provided for skills that dental team members must master, each presented with a goal, materials, chronological steps, and rationales for the performance of each step. Review questions ensure your comprehension of the material and provide practice for classroom and board examinations. Key terms begin each chapter and are highlighted within text discussions and defined in a back-of-book glossary. Chapter learning objectives help you set goals for what you will accomplish and serve as checkpoints for comprehension and study tools in preparation for examinations.
Immune mediators in cancer : Methods and protocols
Provides a comprehensive collection of classic and cutting-edge methodologies as well as bioinformatics and genome-editing approaches that are used to quantify immune mediators and analyze their function and biological activity in cancer cells and tissues. Beginning with a section on the detection of immune mediators in samples, the volume continues with sections covering cytokine bioassays, the expression and regulation of immune mediators in cancer cells, and methods to navigate the enormous datasets created by modern DNA and RNA sequencing and proteomic technology. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.
Languages and Compilers for Parallel Computing ; 20th International Workshop, LCPC 2007, Urbana, IL, USA, October 11-13, 2007, Revised Selected Papers
This book constitutes the thoroughly refereed post-conference proceedings of the 20th International Workshop on Languages and Compilers for Parallel Computing, LCPC 2007, held in Urbana, IL, USA, in October 2007.The 23 revised full papers presented were carefully reviewed and selected from 49 submissions. The papers are organized in topical sections on reliability, languages, parallel compiler technology, libraries, run-time systems and performance analysis, and general compiler techniques.
Checkpoint Responses in Cancer Therapy
This book’s distinguished panel of authors takes a close look at topics ranging from the major molecular players affecting DNA synthesis and the response to DNA damage to advances made in the identification of chemical compounds capable of inhibiting individual mitotic kinases. Illuminating and authoritative, Checkpoint Responses in Cancer Therapy offers a critical summary of findings for researchers in the pharmaceutical and biotechnology industries and a valuable resource for academic scientists in cancer research and the study of cell-cycle regulation, signal transduction and apoptosis.
Cell Cycle Regulation
The cell cycle is tightly regulated on many different levels to ensure properly controlled proliferation. Deregulation of cell cycle regulation is a hallmark of cancer. In this book, many aspects of cell cycle regulation are discussed, which include G1, S, M phase control, ubiquitin-mediated degradation, DNA damage response, mitotic spindle checkpoint, the centrosome cycle, Retinoblastoma protein family, the Myc oncogene, and mouse models for tumor suppressors, cyclin-dependent kinases, and meiosis. These chapters written by experts provide an updated view on how the cell cycle is regulated in vivo and about the involvement of cell cycle regulators in cancer.
Cancerimmunotherapies : Solid tumors and hematologic malignancies
Presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations.
Breast cancer research and treatment : innovative concepts
Focuses on innovative treatment options for breast cancer, including surgery, radiotherapy, systemic therapy and of course immunotherapy that is changing outcomes in some aggressive breast cancer histotypes. Subsequent chapters also address the ongoing emerging research in the screening, diagnostics, and management of all subtypes of breast cancers. All current landscapes and future perspectives in each molecular subtype: luminal, HER2-positive, and triple-negative breast cancers are discussed within the different chapters. Breast cancer is still the most common cancer and cause of cancer deaths among women worldwide. The improvement of breast cancer outcome appears to be strictly related to the validation of precise biomarkers that enable us to better select personalized approaches in breast cancer management. The closing chapters deal with the challenges of low income countries of conducting research in the era of precision medicine for cancer. The book is edited and authored by leading experts in this field and will be of interest for clinicians and scientists alike
Analysis file of drug-induced lung injury : expert opinion for analysis of big data
Describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial.
